Join the Oncology Voice Network. Join for Free
Master Communication Skills to Improve Business Relations
MSL communication skills Medical Affairs engagement KOL and HCP engagement digital tools in MSL communication trends in Medical Affairs

Master Communication Skills to Improve Business Relations


Share This Article


Summary

In this episode, MSL Talk hosts its first live broadcast with panelists Ruth Phillips, Michael Kahn, John Caskey, and Brian Bischel. The conversation centers on enhancing communication skills within MSL teams, tackling deficiencies, and engaging effectively with KOLs and HCPs. The panel discusses internal communication challenges, the misalignment of goals in Medical Affairs, and strategies to combat remote communication fatigue. They explore the impact of digital tools, including social media and AI, on MSL engagement. Audience polls provide insights into stakeholder challenges, and panelists offer solutions for unresponsive stakeholders. The episode concludes with future trends in MSL communication.

The MSL Talk Podcast and Momentum Events teamed up for a first ever LIVE broadcast at the Medical Affairs Xcellence Summit, Philadelphia, PA. The live panel discussion was moderated by MSL Talk Host Tom Caravela and the topic was "Master Communication Skills to Improve Business Relations, and MAXimize Internal and External Engagement". Panelists included Bryan Bishel, Ruth Phillips and Michael Kahn.

The panel discussed:

👉 Training practices, techniques and trends that have been effective in developing communication skills for cross functional influence
👉 What skills need to be developed better for new or even seasoned professionals
👉 How professionals can position themselves better when contacting KOLs, DOLs and HCPs in general, gain better insights and create lasting relationships
👉 How an IIT program helps to drastically improve KOL engagement
👉 What engagement will look like in the next 5 years and what new trends might emerge.

Click for Source
MSL communication skills, Medical Affairs engagement, KOL and HCP engagement, digital tools in MSL, communication trends in Medical Affairs

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Value assessment of oncology drugs using a weighted criterion-based approach
OVN Avatar Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer

Value assessment of oncology drugs using a weighted criterion-based approach

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Article
Outcome measures for oncology alternative payment models: practical considerations and recommendations
OVN Avatar Jakub P. Hlávka, PhD, Pei-Jung Lin, PhD, Peter J. Neumann, ScD

Outcome measures for oncology alternative payment models: practical considerations and recommendations

Article
Leveraging existing data to contextualize phase II clinical trial findings in oncology
OVN Avatar E.M. Ray, L.A. Carey, K.E. Reeder-Hayes

Leveraging existing data to contextualize phase II clinical trial findings in oncology

Article
Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved
OVN Avatar Sean X Zhang, MSc , Dean Fergusson, PhD , Jonathan Kimmelman, PhD

Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved

Article
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
OVN Avatar Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

Explore OVN